Icatibant Fresenius

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency, helping to reduce swelling and improve airway patency.

GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled sourcing and reliable cold‑chain logistics where required. The company adheres to stringent regulatory standards and provides comprehensive documentation for import and distribution.

Icatibant Fresenius is used to manage hereditary angioedema, a bradykinin‑mediated swelling disorder.

- Hereditary angioedema (C1‑inhibitor deficiency): rapidly reduces subcutaneous and submucosal swelling during acute attacks. - Hereditary angioedema (type I and II): provides symptom relief and improves airway patency. - Hereditary angioedema (off‑label prophylaxis): may be employed in selected cases to prevent recurrent episodes.

Icatibant Fresenius may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling at injection site: localized erythema. - Nausea: transient feeling of queasiness. - Headache: mild headache occurring after administration. - Flushing: temporary warmth and reddening of skin.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Severe injection site necrosis: tissue damage at the site. - Thrombocytopenia: low platelet count observed in rare cases. - Acute hypotension: sudden drop in blood pressure. - Angioedema of the face or airway unrelated to hereditary condition (very rare).

When using Icatibant Fresenius, several precautions should be observed to ensure safe administration. - Patient assessment: verify diagnosis of hereditary angioedema and C1‑inhibitor status before use. - Contraindications: avoid in patients with known hypersensitivity to icatibant acetate or any formulation components. - Monitoring: observe for signs of allergic reaction during and after injection. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Concomitant therapy: evaluate interactions with other bradykinin‑targeting agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Fresenius can interact with other medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels, potentially reducing icatibant efficacy. - Angiotensin receptor blockers (ARBs): similar risk of altered bradykinin dynamics.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may affect angioedema frequency. - Other B2 receptor antagonists: additive pharmacologic effect. - Antihistamines: may mask early signs of hypersensitivity.